Insights into the Emerging Therapeutic Targets of Triple-negative Breast Cancer

Arslan, C.; Dizdar, O.; Altundag, K. Pharmacotherapy of triple-negative breast cancer. Expert Opin. Pharmacother., 2009, 10(13), 2081-2093.
[http://dx.doi.org/10.1517/14656560903117309] [PMID: 19640211]

Dent, R.; Trudeau, M.; Pritchard, K.I.; Hanna, W.M.; Kahn, H.K.; Sawka, C.A.; Lickley, L.A.; Rawlinson, E.; Sun, P.; Narod, S.A. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res., 2007, 13(15), 4429-4434.
[http://dx.doi.org/10.1158/1078-0432.CCR-06-3045] [PMID: 17671126]

Aksoy, S.; Dizdar, O.; Harputluoglu, H.; Altundag, K. Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: Single center experience. Ann. Oncol., 2007, 18(11), 1904-1906.
[http://dx.doi.org/10.1093/annonc/mdm487] [PMID: 17993632]

Van Calster, B.; Vanden Bempt, I.; Drijkoningen, M.; Pochet, N.; Cheng, J.; Van Huffel, S.; Hendrickx, W.; Decock, J.; Huang, H-J.; Leunen, K.; Amant, F.; Berteloot, P.; Paridaens, R.; Wildiers, H.; Van Limbergen, E.; Weltens, C.; Timmerman, D.; Van Gorp, T.; Smeets, A.; Van den Bogaert, W.; Vergote, I.; Christiaens, M-R.; Neven, P. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive. Breast Cancer Res. Treat., 2009, 113(1), 181-187.
[http://dx.doi.org/10.1007/s10549-008-9914-7]

Perou, C.M.; Sørlie, T.; Eisen, M.B.; van de Rijn, M.; Jeffrey, S.S.; Rees, C.A.; Pollack, J.R.; Ross, D.T.; Johnsen, H.; Akslen, L.A.; Fluge, Ø.; Pergamenschikov, A.; Williams, C.; Zhu, S.X.; Lønning, P.E.; Børresen-Dale, A.L.; Brown, P.O.; Botstein, D. Molecular portraits of human breast tumours. Nature, 2000, 406(6797), 747-752.
[http://dx.doi.org/10.1038/35021093] [PMID: 10963602]

Nielsen, T.O.; Hsu, F.D.; Jensen, K.; Cheang, M.; Karaca, G.; Hu, Z.; Hernandez-Boussard, T.; Livasy, C.; Cowan, D.; Dressler, L.; Akslen, L.A.; Ragaz, J.; Gown, A.M.; Gilks, C.B.; van de Rijn, M.; Perou, C.M. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res., 2004, 10(16), 5367-5374.
[http://dx.doi.org/10.1158/1078-0432.CCR-04-0220] [PMID: 15328174]

Couch, F. Genetic epidemiology of BRCA1. Cancer Biol. Ther., 2004, 3(6), 509-514.
[http://dx.doi.org/10.4161/cbt.3.6.840] [PMID: 15254414]

Chen, Q.J.; Wang, Y-A.; Situ, H-L.; Lu, D-M.; Ren, L-P.; Lai, X-W.; Liu, P-X.; Lin, Y. Effects of runing recipeⅡ on expressions of p53 and ras oncogene proteins and cell cycle of the transplanted Ca761 breast cancer in mice. J. Chin. Integr. Med., 2005, 3(3), 225-228.
[http://dx.doi.org/10.3736/jcim20050317] [PMID: 15885175]

Hanahan, D.; Coussens, L.M. Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell, 2012, 21(3), 309-322.
[http://dx.doi.org/10.1016/j.ccr.2012.02.022] [PMID: 22439926]

Nilendu, P.; Sarode, S.C.; Jahagirdar, D.; Tandon, I.; Patil, S.; Sarode, G.S.; Pal, J.K.; Sharma, N.K. Mutual concessions and compromises between stromal cells and cancer cells: Driving tumor development and drug resistance. Cell Oncol., 2018, 41(4), 353-367.
[http://dx.doi.org/10.1007/s13402-018-0388-2] [PMID: 30027403]

Badodekar, N.; Sharma, A.; Patil, V.; Telang, G.; Sharma, R.; Patil, S.; Vyas, N.; Somasundaram, I. Angiogenesis induction in breast cancer: A paracrine paradigm. Cell Biochem. Funct., 2021, 39(7), 860-873.
[http://dx.doi.org/10.1002/cbf.3663] [PMID: 34505714]

Carmeliet, P.; Jain, R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature, 2011, 473(7347), 298-307.
[http://dx.doi.org/10.1038/nature10144] [PMID: 21593862]

Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86(3), 353-364.
[http://dx.doi.org/10.1016/S0092-8674(00)80108-7] [PMID: 8756718]

Messeha, S.S.; Zarmouh, N.O.; Antonie, L.; Soliman, K.F.A. Sanguinarine inhibition of TNF-α-induced CCL2, IKBKE/NF-κB/ERK1/2 signaling pathway, and cell migration in human triple-negative breast cancer cells. Int J Mol Sci, 2022, 23(15), 8329.
[http://dx.doi.org/10.3390/ijms23158329]

Hao, Q.; Vadgama, J.V.; Wang, P. CCL2/CCR2 signaling in cancer pathogenesis. Cell Commun. Signal., 2020, 18(1), 82.
[http://dx.doi.org/10.1186/s12964-020-00589-8] [PMID: 32471499]

Vaupel, P.; Höckel, M.; Mayer, A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid. Redox Signal., 2007, 9(8), 1221-1236.
[http://dx.doi.org/10.1089/ars.2007.1628] [PMID: 17536958]

Liedtke, C.; Mazouni, C.; Hess, K.R.; André, F.; Tordai, A.; Mejia, J.A.; Symmans, W.F.; Gonzalez-Angulo, A.M.; Hennessy, B.; Green, M.; Cristofanilli, M.; Hortobagyi, G.N.; Pusztai, L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol., 2008, 26(8), 1275-1281.
[http://dx.doi.org/10.1200/JCO.2007.14.4147] [PMID: 18250347]

Carey, L.A.; Dees, E.C.; Sawyer, L.; Gatti, L.; Moore, D.T.; Collichio, F.; Ollila, D.W.; Sartor, C.I.; Graham, M.L.; Perou, C.M. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res., 2007, 13(8), 2329-2334.
[http://dx.doi.org/10.1158/1078-0432.CCR-06-1109] [PMID: 17438091]

Diana, A.; Franzese, E.; Centonze, S.; Carlino, F.; Della Corte, C.M.; Ventriglia, J.; Petrillo, A.; De Vita, F.; Alfano, R.; Ciardiello, F.; Orditura, M. Triple-negative breast cancers: Systematic review of the literature on molecular and clinical features with a focus on treatment with innovative drugs. Curr. Oncol. Rep., 2018, 20(10), 76.
[http://dx.doi.org/10.1007/s11912-018-0726-6] [PMID: 30128845]

Xiang, L.; Gilkes, D.M.; Chaturvedi, P.; Luo, W.; Hu, H.; Takano, N.; Liang, H.; Semenza, G.L. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer. J. Mol. Med., 2014, 92, 151-164.

Zoltán, S.; Koch, A.E.Z. Mechanisms of disease: Angiogenesis in inflammatory diseases. Nat Clin Pract Rheumatol, 3(11), 635-643.

Tang, J.; Li, Z.; Lu, L.; Cho, C.H. β-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin. Cancer Biol., 2013, 23(6), 533-542.
[http://dx.doi.org/10.1016/j.semcancer.2013.08.009] [PMID: 24012659]

Driffort, V.; Gillet, L.; Bon, E.; Marionneau-Lambot, S.; Oullier, T.; Joulin, V.; Collin, C.; Pagès, J.C.; Jourdan, M.L.; Chevalier, S.; Bougnoux, P.; Le Guennec, J.Y.; Besson, P.; Roger, S. Ranolazine inhibits NaV1.5-mediated breast cancer cell invasiveness and lung colonization. Mol. Cancer, 2014, 13(1), 264.
[http://dx.doi.org/10.1186/1476-4598-13-264] [PMID: 25496128]

Fraser, S.P.; Diss, J.K.J.; Chioni, A.M.; Mycielska, M.E.; Pan, H.; Yamaci, R.F.; Pani, F.; Siwy, Z.; Krasowska, M.; Grzywna, Z.; Brackenbury, W.J.; Theodorou, D.; Koyutürk, M.; Kaya, H.; Battaloglu, E.; De Bella, M.T.; Slade, M.J.; Tolhurst, R.; Palmieri, C.; Jiang, J.; Latchman, D.S.; Coombes, R.C.; Djamgoz, M.B.A. Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin. Cancer Res., 2005, 11(15), 5381-5389.
[http://dx.doi.org/10.1158/1078-0432.CCR-05-0327] [PMID: 16061851]

Speyer, C.L.; Nassar, M.A.; Hachem, A.H.; Bukhsh, M.A.; Jafry, W.S.; Khansa, R.M.; Gorski, D.H. Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1. Breast Cancer Res. Treat., 2016, 157(2), 217-228.
[http://dx.doi.org/10.1007/s10549-016-3816-x] [PMID: 27146584]

Zhu, S.; Wu, Y.; Song, B.; Yi, M.; Yan, Y.; Mei, Q.; Wu, K. Recent advances in targeted strategies for triple-negative breast cancer. J. Hematol. Oncol., 2023, 16(1), 100.
[http://dx.doi.org/10.1186/s13045-023-01497-3] [PMID: 37641116]

Eikesdal, H.P.; Yndestad, S.; Elzawahry, A.; Llop-Guevara, A.; Gilje, B.; Blix, E.S.; Espelid, H.; Lundgren, S.; Geisler, J.; Vagstad, G.; Venizelos, A.; Minsaas, L.; Leirvaag, B.; Gudlaugsson, E.G.; Vintermyr, O.K.; Aase, H.S.; Aas, T.; Balmaña, J.; Serra, V.; Janssen, E.A.M.; Knappskog, S.; Lønning, P.E. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Ann. Oncol., 2021, 32(2), 240-249.
[http://dx.doi.org/10.1016/j.annonc.2020.11.009] [PMID: 33242536]

Robson, M.E.; Tung, N.; Conte, P.; Im, S.A.; Senkus, E.; Xu, B.; Masuda, N.; Delaloge, S.; Li, W.; Armstrong, A.; Wu, W.; Goessl, C.; Runswick, S.; Domchek, S.M. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann. Oncol., 2019, 30(4), 558-566.
[http://dx.doi.org/10.1093/annonc/mdz012] [PMID: 30689707]

Tutt, A.N.J.; Garber, J.E.; Kaufman, B.; Viale, G.; Fumagalli, D.; Rastogi, P.; Gelber, R.D.; de Azambuja, E.; Fielding, A.; Balmaña, J.; Domchek, S.M.; Gelmon, K.A.; Hollingsworth, S.J.; Korde, L.A.; Linderholm, B.; Bandos, H.; Senkus, E.; Suga, J.M.; Shao, Z.; Pippas, A.W.; Nowecki, Z.; Huzarski, T.; Ganz, P.A.; Lucas, P.C.; Baker, N.; Loibl, S.; McConnell, R.; Piccart, M.; Schmutzler, R.; Steger, G.G.; Costantino, J.P.; Arahmani, A.; Wolmark, N.; McFadden, E.; Karantza, V.; Lakhani, S.R.; Yothers, G.; Campbell, C.; Geyer, C.E. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med, 2021, 384(25), 2394-2405.
[http://dx.doi.org/10.1056/NEJMoa2105215]

Litton, J.K.; Scoggins, M.E.; Hess, K.R.; Adrada, B.E.; Murthy, R.K.; Damodaran, S.; DeSnyder, S.M.; Brewster, A.M.; Barcenas, C.H.; Valero, V.; Whitman, G.J.; Schwartz-Gomez, J.; Mittendorf, E.A.; Thompson, A.M.; Helgason, T.; Ibrahim, N.; Piwnica-Worms, H.; Moulder, S.L.; Arun, B.K. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J. Clin. Oncol., 2020, 38(5), 388-394.
[http://dx.doi.org/10.1200/JCO.19.01304] [PMID: 31461380]

Beniey, M.; Hubert, A.; Haque, T.; Cotte, A.K.; Béchir, N.; Zhang, X.; Tran-Thanh, D.; Hassan, S. Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer. Br. J. Cancer, 2023, 128(10), 1964-1975.
[http://dx.doi.org/10.1038/s41416-023-02226-w] [PMID: 36941406]

Bianchini, G.; De Angelis, C.; Licata, L.; Gianni, L. Treatment landscape of triple-negative breast cancer — expanded options, evolving needs. Nat. Rev. Clin. Oncol., 2022, 19(2), 91-113.
[http://dx.doi.org/10.1038/s41571-021-00565-2] [PMID: 34754128]

Luo, J.; Jin, J.; Yang, F.; Sun, Z.; Zhang, W.; Shi, Y.; Xu, J.; Guan, X. The correlation between PARP1 and BRCA1 in AR positive triple-negative breast cancer. Int. J. Biol. Sci., 2016, 12(12), 1500-1510.
[http://dx.doi.org/10.7150/ijbs.16176] [PMID: 27994514]

Lehmann, B.D.; Abramson, V.G.; Sanders, M.E.; Mayer, E.L.; Haddad, T.C.; Nanda, R.; Van Poznak, C.; Storniolo, A.M.; Nangia, J.R.; Gonzalez-Ericsson, P.I.; Sanchez, V.; Johnson, K.N.; Abramson, R.G.; Chen, S.C.; Shyr, Y.; Arteaga, C.L.; Wolff, A.C.; Pietenpol, J.A. TBCRC 032 IB/II multicenter study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer. Clin. Cancer Res., 2020, 26(9), 2111-2123.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-2170] [PMID: 31822498]

Pascual, J.; Turner, N.C. Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann. Oncol., 2019, 30(7), 1051-1060.
[http://dx.doi.org/10.1093/annonc/mdz133] [PMID: 31050709]

Nicholson, K.M.; Quinn, D.M.; Kellett, G.L.; Warr, J.R. LY294002, an inhibitor of phosphatidylinositol-3-kinase, causes preferential induction of apoptosis in human multidrug resistant cells. Cancer Lett., 2003, 190(1), 31-36.
[http://dx.doi.org/10.1016/S0304-3835(02)00615-8] [PMID: 12536074]

Joshi, S.; Singh, A.R.; Durden, D.L. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma. Cancer Chemother. Pharmacol., 2015, 75(3), 595-608.
[http://dx.doi.org/10.1007/s00280-014-2639-x] [PMID: 25578041]

Mahadevan, D.; Chiorean, E.G.; Harris, W.B.; Von Hoff, D.D.; Stejskal-Barnett, A.; Qi, W.; Anthony, S.P.; Younger, A.E.; Rensvold, D.M.; Cordova, F.; Shelton, C.F.; Becker, M.D.; Garlich, J.R.; Durden, D.L.; Ramanathan, R.K. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer, 2012, 48(18), 3319-3327.
[http://dx.doi.org/10.1016/j.ejca.2012.06.027]

Oliveira, M.; Saura, C.; Nuciforo, P.; Calvo, I.; Andersen, J.; Passos-Coelho, J.L.; Gil Gil, M.; Bermejo, B.; Patt, D.A.; Ciruelos, E.; de la Peña, L.; Xu, N.; Wongchenko, M.; Shi, Z.; Singel, S.M.; Isakoff, S.J. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Ann. Oncol., 2019, 30(8), 1289-1297.
[http://dx.doi.org/10.1093/annonc/mdz177] [PMID: 31147675]

Wu, X.; Xu, Y.; Liang, Q.; Yang, X.; Huang, J.; Wang, J.; Zhang, H.; Shi, J. Recent advances in dual PI3K/mTOR inhibitors for tumour treatment. Front. Pharmacol., 2022, 13, 875372.
[http://dx.doi.org/10.3389/fphar.2022.875372] [PMID: 35614940]

Cerma, K.; Piacentini, F.; Moscetti, L.; Barbolini, M.; Canino, F.; Tornincasa, A.; Caggia, F.; Cerri, S.; Molinaro, A.; Dominici, M.; Omarini, C. Targeting PI3K/AKT/mTOR pathway in breast cancer: From biology to clinical challenges. Biomedicines, 2023, 11(1), 109.
[http://dx.doi.org/10.3390/biomedicines11010109] [PMID: 36672617]

Sobande, F.; Dušek, L.; Matějková, A.; Rozkoš, T.; Laco, J.; Ryška, A. EGFR in triple negative breast carcinoma: Significance of protein expression and high gene copy number. Cesk. Patol., 2015, 51(2), 80-86.
[PMID: 25970719]

Sabbah, D.A.; Hajjo, R.; Sweidan, K. Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr. Top. Med. Chem., 2020, 20(10), 815-834.
[http://dx.doi.org/10.2174/1568026620666200303123102] [PMID: 32124699]

Corkery, B.; Crown, J.; Clynes, M.; O’Donovan, N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann. Oncol., 2009, 20(5), 862-867.
[http://dx.doi.org/10.1093/annonc/mdn710] [PMID: 19150933]

Baselga, J.; Gómez, P.; Greil, R.; Braga, S.; Climent, M.A.; Wardley, A.M.; Kaufman, B.; Stemmer, S.M.; Pêgo, A.; Chan, A.; Goeminne, J.C.; Graas, M.P.; Kennedy, M.J.; Ciruelos Gil, E.M.; Schneeweiss, A.; Zubel, A.; Groos, J.; Melezínková, H.; Awada, A. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J. Clin. Oncol., 2013, 31(20), 2586-2592.
[http://dx.doi.org/10.1200/JCO.2012.46.2408] [PMID: 23733761]

Tang, A.H.; Hoefer, R.A.; Guye, M.L.; Bear, H.D. Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer. Cancer Drug Resist., 2022, 5(3), 691-702.
[http://dx.doi.org/10.20517/cdr.2022.31] [PMID: 36176751]

Hegde, P.S.; Wallin, J.J.; Mancao, C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin. Cancer Biol., 2018, 52(Pt 2), 117-124.
[http://dx.doi.org/10.1016/j.semcancer.2017.12.002] [PMID: 29229461]

Robert, N.J.; Diéras, V.; Glaspy, J.; Brufsky, A.M.; Bondarenko, I.; Lipatov, O.N.; Perez, E.A.; Yardley, D.A.; Chan, S.Y.T.; Zhou, X.; Phan, S.C.; O’Shaughnessy, J. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol., 2011, 29(10), 1252-1260.
[http://dx.doi.org/10.1200/JCO.2010.28.0982] [PMID: 21383283]

Gerber, B.; von Minckwitz, G.; Eidtmann, H.; Rezai, M.; Fasching, P.; Tesch, H.; Eggemann, H.; Schrader, I.; Kittel, K.; Hanusch, C.; Solbach, C.; Jackisch, C.; Kunz, G.; Blohmer, J.U.; Huober, J.; Hauschild, M.; Nekljudova, V.; Loibl, S.; Untch, M. Surgical outcome after neoadjuvant chemotherapy and bevacizumab: Results from the GeparQuinto study (GBG 44). Ann. Surg. Oncol., 2014, 21(8), 2517-2524.
[http://dx.doi.org/10.1245/s10434-014-3606-9] [PMID: 24740826]

Loibl, S.; Weber, K.E.; Timms, K.M.; Elkin, E.P.; Hahnen, E.; Fasching, P.A.; Lederer, B.; Denkert, C.; Schneeweiss, A.; Braun, S.; Salat, C.T.; Rezai, M.; Blohmer, J.U.; Zahm, D.M.; Jackisch, C.; Gerber, B.; Klare, P.; Kümmel, S.; Schem, C.; Paepke, S.; Schmutzler, R.; Rhiem, K.; Penn, S.; Reid, J.; Nekljudova, V.; Hartman, A.R.; von Minckwitz, G.; Untch, M. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto. Ann. Oncol., 2018, 29(12), 2341-2347.
[http://dx.doi.org/10.1093/annonc/mdy460] [PMID: 30335131]

Bell, R.; Brown, J.; Parmar, M.; Toi, M.; Suter, T.; Steger, G.G.; Pivot, X.; Mackey, J.; Jackisch, C.; Dent, R.; Hall, P.; Xu, N.; Morales, L.; Provencher, L.; Hegg, R.; Vanlemmens, L.; Kirsch, A.; Schneeweiss, A.; Masuda, N.; Overkamp, F.; Cameron, D. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Ann. Oncol., 2017, 28(4), 754-760.
[http://dx.doi.org/10.1093/annonc/mdw665] [PMID: 27993816]

Howard, F.M.; Pearson, A.T.; Nanda, R. Clinical trials of immunotherapy in triple-negative breast cancer. Breast Cancer Res. Treat., 2022, 195(1), 1-15.
[http://dx.doi.org/10.1007/s10549-022-06665-6] [PMID: 35834065]

Kimmick, G.; Ratain, M.J.; Berry, D.; Woolf, S.; Norton, L.; Muss, H.B. Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: A phase II study of the Cancer and Leukemia Group B (CALGB 9041). Invest. New Drugs, 2004, 22(1), 83-89.
[http://dx.doi.org/10.1023/B:DRUG.0000006178.32718.22] [PMID: 14707498]

Loi, S.; Sirtaine, N.; Piette, F.; Salgado, R.; Viale, G.; Van Eenoo, F.; Rouas, G.; Francis, P.; Crown, J.P.A.; Hitre, E.; de Azambuja, E.; Quinaux, E.; Di Leo, A.; Michiels, S.; Piccart, M.J.; Sotiriou, C. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol., 2013, 31(7), 860-867.
[http://dx.doi.org/10.1200/JCO.2011.41.0902] [PMID: 23341518]

Adams, S.; Gray, R.J.; Demaria, S.; Goldstein, L.; Perez, E.A.; Shulman, L.N.; Martino, S.; Wang, M.; Jones, V.E.; Saphner, T.J.; Wolff, A.C.; Wood, W.C.; Davidson, N.E.; Sledge, G.W.; Sparano, J.A.; Badve, S.S. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J. Clin. Oncol., 2014, 32(27), 2959-2966.
[http://dx.doi.org/10.1200/JCO.2013.55.0491] [PMID: 25071121]

Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature, 2012, 490(7418), 61-70.
[http://dx.doi.org/10.1038/nature11412] [PMID: 23000897]

Nanda, R.; Chow, L.Q.M.; Dees, E.C.; Berger, R.; Gupta, S.; Geva, R.; Pusztai, L.; Pathiraja, K.; Aktan, G.; Cheng, J.D.; Karantza, V.; Buisseret, L. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. J. Clin. Oncol., 2016, 34(21), 2460-2467.
[http://dx.doi.org/10.1200/JCO.2015.64.8931] [PMID: 27138582]

Adams, S.; Schmid, P.; Rugo, H.S.; Winer, E.P.; Loirat, D.; Awada, A.; Cescon, D.W.; Iwata, H.; Campone, M.; Nanda, R.; Hui, R.; Curigliano, G.; Toppmeyer, D.; O’Shaughnessy, J.; Loi, S.; Paluch-Shimon, S.; Tan, A.R.; Card, D.; Zhao, J.; Karantza, V.; Cortés, J. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study. Ann. Oncol., 2019, 30(3), 397-404.
[http://dx.doi.org/10.1093/annonc/mdy517] [PMID: 30475950]

Cortés, J.; Lipatov, O.; Im, S.A.; Gonçalves, A.; Lee, K.S.; Schmid, P.; Tamura, K.; Testa, L.; Witzel, I.; Ohtani, S.; Zambelli, S.; Harbeck, N.; André, F.; Dent, R.; Zhou, X.; Karantza, V.; Mejia, J.A.; Winer, E.P. KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC). Ann. Oncol., 2019, 30, v859-v860.
[http://dx.doi.org/10.1093/annonc/mdz394.010]

Schmid, P.; Haiderali, A.; Mejia, J.; Guo, Z.; Zhou, X.; Martin-Nguyen, A.; Cortés, J.; Winer, E. 141P Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer. Ann. Oncol., 2020, 31, S65-S66.
[http://dx.doi.org/10.1016/j.annonc.2020.03.242]

Cortes, J.; Cescon, D.W.; Rugo, H.S.; Nowecki, Z.; Im, S.A.; Yusof, M.M.; Gallardo, C.; Lipatov, O.; Barrios, C.H.; Holgado, E.; Iwata, H.; Masuda, N.; Otero, M.T.; Gokmen, E.; Loi, S.; Guo, Z.; Zhao, J.; Aktan, G.; Karantza, V.; Schmid, P.; Luis, F.; Gonzalo, G.A.; Diego, K.; Ruben, K.; Matias, M.; Mirta, V.; Sally, B.H.; Stephen, B.; Philip, C.; Sherene, L.; Dhanusha, S.; Andrea, G.; Donatienne, T.; Carlos, B.; Leandro, B.; Fabiano, C.; Ruffo, F.J.; Roberto, H.; Carvalho, D.L.; Toniazzi, F.C.L.; Odebrecht, R.R.; Orlando, A.S.N.; Felipe, S.; David, C.; Danielle, C.; Cristiano, F.; Xinni, S.; Joanne, Y.; Alejandro, A.; Carlos, G.; Claudio, S.; Cesar, S.; Eduardo, Y.; Alvaro, G.D.; Jesus, S.; Petra, H.; Zdenek, K.; Bohuslav, M.; Katarina, P.; Jana, P.; Vesna, G.; Erik, J.; Jeanette, J.; Soren, L.; Tamas, L.; Herve, B.; Isabelle, D.; Anthony, G.; Anne-Claire, H.B.; Luis, T.; Jens-Uwe, B.; Peter, F.; Dirk, F.; Nadia, H.; Jens, H.; Anna, K.F.S.; Christian, K.; Sibylle, L.; Diana, L.; Tjoung-Won, P.S.; Raquel Von, S.; Pauline, W.; Louis, C.; Ava, K.; Roger, K.C.N.; Peter, A.; Tibor, C.; Zsuzsanna, K.; Laszlo, L.; Karoly, M.; Gabor, R.; John, C.; Catherine, K.; Seamus, O.R.; Saverio, C.; Antonietta, D.A.; Enrico, R.; Tomoyuki, A.; Takaaki, F.; Kenichi, I.; Takashi, I.; Yoshinori, I.; Tsutomu, I.; Hiroji, I.; Yoshimasa, K.; Koji, M.; Yasuo, M.; Hirofumi, M.; Seigo, N.; Naoki, N.; Shoichiro, O.; Akihiko, O.; Yasuaki, S.; Eiji, S.; Masato, T.; Yuko, T.; Kenji, T.; Koichiro, T.; Junichiro, W.; Naohito, Y.; Yutaka, Y.; Teruo, Y.; Anita, B.; Mastura, M.Y.; Angel, G.V.; Alejandro, J.R.; Jorge, M.R.; Flavia, M.V.; Jessica, R.C.; Karin, B.; Vivianne, T.H.; David, P.; Ewa, C.; Ewa, N.Z.; Zbigniew, N.; Barbara, R.; Joanna, S.; Cezary, S.; Rafal, T.; Bogdan, Z.; Alexander, A.; Natalia, F.; Oleg, L.; Andrey, M.; Vladimir, M.; Guzel, M.; Jin Hee, A.; Seock-Ah, I.; Keun Seok, L.; Kwong Hwa, P.; Yeon Hee, P.; Begona, B.H.; Javier, C.; Josefina, C.J.; Luis, C.M.; Jose, G.S.; Maria, G.; Esther, H.; Esther, Z.A.; Chien-Ting, L.; Mei-Ching, L.; Chiun-Sheng, H.; Chao-Jung, T.; Ling-Ming, T.; Cagatay, A.; Gul, B.; Irfan, C.; Erhan, G.; Seyda, G.; Nil, M.M.; Mustafa, O.; Ozgur, O.; Sinan, Y.; Steve, C.; Janine, G.; Iain, M.; Peter, S.; Nicholas, T.; Mark, T.; Christopher, T.; Duncan, W.; Hryhoriy, A.; Oleksandr, B.; Igor, B.; Oleksii, K.; Olena, K.; Hanna, K.; Anna, K.; Iurii, L.; Alla, N.; Natalya, O.; Olga, P.; Andrii, R.; Sergii, S.; Yaroslav, S.; Dmytro, T.; Grygorii, U.; Ihor, V.; Sibel, B.; Madhu, C.; Michael, C.; Patrick, C.; Scott, C.; Jennifer, D.; Keerthi, G.; Jeffrey, H.; Kent, H.; William, I.; Randa, L.; Janice, L.; Raul, M.; Susan, M.; Rita, N.; Ira, O.; Coral, O.; Timothy, P.; Amit, P.; Brian, P.; Hope, R.; Irina, R.; Michael, S.; Robert, S.; Michael, S.; Laura, S.; Bradley, S.; Michaela, T.; Frances, V.A. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet, 2020, 396(10265), 1817-1828.
[http://dx.doi.org/10.1016/S0140-6736(20)32531-9] [PMID: 33278935]

Shah, A.N.; Flaum, L.; Helenowski, I.; Santa-Maria, C.A.; Jain, S.; Rademaker, A.; Nelson, V.; Tsarwhas, D.; Cristofanilli, M.; Gradishar, W. Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer. J. Immunother. Cancer, 2020, 8(1), e000173.
[http://dx.doi.org/10.1136/jitc-2019-000173] [PMID: 32060053]

Baar, J.; Abraham, J.; Budd, G.T.; Silverman, P.; Montero, A.; Moore, H.; Fu, P.; Varadan, V.; Ladaika, K.; Hricik, L. Abstract PS12-16: Pilot study of carboplatin, nab-paclitaxel and pembrolizumab for metastatic triple-negative breast cancer. Cancer Res., 2021, 81(S4), PS12-16.
[http://dx.doi.org/10.1158/1538-7445.SABCS20-PS12-16]

Wang, G.L.; Jiang, B.H.; Rue, E.A.; Semenza, G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci., 1995, 92(12), 5510-5514.
[http://dx.doi.org/10.1073/pnas.92.12.5510] [PMID: 7539918]

Li, S.; Wei, Q.; Li, Q.; Zhang, B.; Xiao, Q. Down-regulating HIF-1α by lentivirus-mediated shRNA for therapy of triple negative breast cancer. Cancer Biol. Ther., 2015, 16(6), 866-875.
[http://dx.doi.org/10.1080/15384047.2015.1040958] [PMID: 25920936]

Prabhakar, N.R.; Semenza, G.L. Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol. Rev., 2012, 92(3), 967-1003.
[http://dx.doi.org/10.1152/physrev.00030.2011] [PMID: 22811423]

Minet, E.; Mottet, D.; Michel, G.; Roland, I.; Raes, M.; Remacle, J.; Michiels, C. Hypoxia-induced activation of HIF-1: Role of HIF-1α-Hsp90 interaction. FEBS Lett., 1999, 460(2), 251-256.
[http://dx.doi.org/10.1016/S0014-5793(99)01359-9] [PMID: 10544245]

Agani, F.; Jiang, B.H. Oxygen-independent regulation of HIF-1: Novel involvement of PI3K/AKT/mTOR pathway in cancer. Curr. Cancer Drug Targets, 2013, 13(3), 245-251.
[http://dx.doi.org/10.2174/1568009611313030003] [PMID: 23297826]

El Guerrab, A.; Zegrour, R.; Nemlin, C.C.; Vigier, F.; Cayre, A.; Penault-Llorca, F.; Rossignol, F.; Bignon, Y.J. Differential impact of EGFR-targeted therapies on hypoxia responses: Implications for treatment sensitivity in triple-negative metastatic breast cancer. PLoS One, 2011, 6(9), e25080.
[http://dx.doi.org/10.1371/journal.pone.0025080] [PMID: 21966417]

Semenza, G.L. Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene, 2013, 32(35), 4057-4063.
[http://dx.doi.org/10.1038/onc.2012.578] [PMID: 23222717]

Semenza, G.L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest., 2013, 123(9), 3664-3671.
[http://dx.doi.org/10.1172/JCI67230] [PMID: 23999440]

Forsythe, J.A.; Jiang, B.H.; Iyer, N.V.; Agani, F.; Leung, S.W.; Koos, R.D.; Semenza, G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol., 1996, 16(9), 4604-4613.
[http://dx.doi.org/10.1128/MCB.16.9.4604] [PMID: 8756616]

Ceradini, D.J.; Kulkarni, A.R.; Callaghan, M.J.; Tepper, O.M.; Bastidas, N.; Kleinman, M.E.; Capla, J.M.; Galiano, R.D.; Levine, J.P.; Gurtner, G.C. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med., 2004, 10(8), 858-864.
[http://dx.doi.org/10.1038/nm1075] [PMID: 15235597]

Chaturvedi, P.; Gilkes, D.M.; Wong, C.C.L.; Kshitiz; Luo, W.; Zhang, H.; Wei, H.; Takano, N.; Schito, L.; Levchenko, A.; Semenza, G.L. Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis. J. Clin. Invest., 2012, 123(1), 189-205.
[http://dx.doi.org/10.1172/JCI64993] [PMID: 23318994]

Choi, J.Y.; Jang, Y.S.; Min, S.Y.; Song, J.Y. Overexpression of MMP-9 and HIF-1α in breast cancer cells under hypoxic conditions. J. Breast Cancer, 2011, 14(2), 88-95.
[http://dx.doi.org/10.4048/jbc.2011.14.2.88] [PMID: 21847402]

Wong, C.C.L.; Gilkes, D.M.; Zhang, H.; Chen, J.; Wei, H.; Chaturvedi, P.; Fraley, S.I.; Wong, C.M.; Khoo, U.S.; Ng, I.O.L.; Wirtz, D.; Semenza, G.L. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc. Natl. Acad. Sci., 2011, 108(39), 16369-16374.
[http://dx.doi.org/10.1073/pnas.1113483108] [PMID: 21911388]

Liu, Q.; Guan, C.; Liu, C.; Li, H.; Wu, J.; Sun, C. Targeting hypoxia-inducible factor-1alpha: A new strategy for triple-negative breast cancer therapy. Biomed. Pharmacother., 2022, 156, 113861.
[http://dx.doi.org/10.1016/j.biopha.2022.113861] [PMID: 36228375]

Esfandiary, A.; Taherian-Esfahani, Z.; Abedin-Do, A.; Mirfakhraie, R.; Shirzad, M.; Ghafouri-Fard, S.; Motevaseli, E. Lactobacilli modulate hypoxia-inducible factor (HIF)-1 regulatory pathway in triple negative breast cancer cell line. Cell J., 2016, 18(2), 237-244.
[http://dx.doi.org/10.22074/cellj.2016.4319] [PMID: 27540529]

Wang, F.; Miaomiao, C; Shi, Y.; Jiang, L.; Zhao, J.; Hai, L.; Sharen, G.; Du, H. Down-regulation of hypoxia-inducible factor-1 suppresses malignant biological behavior of triple-negative breast cancer cells. Int J Clin Exp Med., 2014, 7(11), 3933-3940. n.d.

Kim, D.H.; Sung, B.; Kim, J.A.; Kang, Y.J.; Hwang, S.Y.; Hwang, N.L.; Suh, H.; Choi, Y.H.; Im, E.; Chung, H.Y.; Kim, N.D. HS-1793, a resveratrol analogue, downregulates the expression of hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human breast cancer cells in a nude mouse xenograft model. Int. J. Oncol., 2017, 51(2), 715-723.
[http://dx.doi.org/10.3892/ijo.2017.4058] [PMID: 28656256]

Yurasakpong, L.; Apisawetakan, S.; Pranweerapaiboon, K.; Sobhon, P.; Chaithirayanon, K. Holothuria scabra extract induces cell apoptosis and suppresses warburg effect by down-regulating Akt/mTOR/HIF-1 axis in MDA-MB-231 breast cancer cells. Nutr. Cancer, 2021, 73(10), 1964-1975.
[http://dx.doi.org/10.1080/01635581.2020.1814825] [PMID: 32878490]

Bailey, C.M.; Liu, Y.; Peng, G.; Zhang, H.; He, M.; Sun, D.; Zheng, P.; Liu, Y.; Wang, Y. Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer. Nanomedicine, 2020, 29, 102278.
[http://dx.doi.org/10.1016/j.nano.2020.102278] [PMID: 32738299]

Wang, K.L.; Hsia, S.M.; Chan, C.J.; Chang, F.Y.; Huang, C.Y.; Bau, D.T.; Wang, P.S. Inhibitory effects of isoliquiritigenin on the migration and invasion of human breast cancer cells. Expert Opin. Ther. Targets, 2013, 17(4), 337-349.
[http://dx.doi.org/10.1517/14728222.2013.756869] [PMID: 23327692]

Mir Hassani, Z.; Nabiuni, M.; Parivar, K.; Abdirad, S.; Karimzadeh, L. Melittin inhibits the expression of key genes involved in tumor microenvironment formation by suppressing HIF-1α signaling in breast cancer cells. Med. Oncol., 2021, 38(7), 77.
[http://dx.doi.org/10.1007/s12032-021-01526-6] [PMID: 34076777]

Jin, J.; Qiu, S.; Wang, P.; Liang, X.; Huang, F.; Wu, H.; Zhang, B.; Zhang, W.; Tian, X.; Xu, R.; Shi, H.; Wu, X. Cardamonin inhibits breast cancer growth by repressing HIF-1α-dependent metabolic reprogramming. J. Exp. Clin. Cancer Res., 2019, 38(1), 377.
[http://dx.doi.org/10.1186/s13046-019-1351-4] [PMID: 31455352]

Wu, S.; Zhang, L.; Li, H.; Xu, J.; Jiang, C.; Sun, T. Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: Study protocol for a randomized controlled clinical trial. Trials, 2020, 21(1), 420.
[http://dx.doi.org/10.1186/s13063-020-04342-x] [PMID: 32448335]

Guo, C.H.; Hsia, S.; Chung, C.H.; Lin, Y.C.; Shih, M.Y.; Chen, P.C.; Peng, C.L.; Henning, S.M.; Hsu, G.S.W.; Li, Z. Nutritional supplements in combination with chemotherapy or targeted therapy reduces tumor progression in mice bearing triple-negative breast cancer. J. Nutr. Biochem., 2021, 87, 108504.
[http://dx.doi.org/10.1016/j.jnutbio.2020.108504] [PMID: 32956826]

Naik, A.; Decock, J. Lactate metabolism and immune modulation in breast cancer: A focused review on triple negative breast tumors. Front. Oncol., 2020, 10, 598626.
[http://dx.doi.org/10.3389/fonc.2020.598626] [PMID: 33324565]

Parks, W.C.; Wilson, C.L.; López-Boado, Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol., 2004, 4(8), 617-629.
[http://dx.doi.org/10.1038/nri1418] [PMID: 15286728]

Stamenkovic, I. Extracellular matrix remodelling: The role of matrix metalloproteinases. J. Pathol., 2003, 200(4), 448-464.
[http://dx.doi.org/10.1002/path.1400] [PMID: 12845612]

Chien, Y-C.; Liu, L-C.; Ye, H-Y.; Wu, J-Y.; Yu, Y-L. EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway. Am. J. Cancer Res., 2018, 8(3), 422-434.
[PMID: 29636998]

Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell, 2010, 141(1), 52-67.
[http://dx.doi.org/10.1016/j.cell.2010.03.015] [PMID: 20371345]

Gialeli, C.; Theocharis, A.D.; Karamanos, N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J., 2011, 278(1), 16-27.
[http://dx.doi.org/10.1111/j.1742-4658.2010.07919.x] [PMID: 21087457]

Radisky, E.S.; Radisky, D.C. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J. Mammary Gland Biol. Neoplasia, 2010, 15(2), 201-212.
[http://dx.doi.org/10.1007/s10911-010-9177-x] [PMID: 20440544]

Mehner, C.; Hockla, A.; Miller, E.; Ran, S.; Radisky, D.C.; Radisky, E.S. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget, 2014, 5(9), 2736-2749.
[http://dx.doi.org/10.18632/oncotarget.1932] [PMID: 24811362]

Guo, H.; Li, R.; Zucker, S.; Toole, B.P. EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res., 2000, 60(4), 888-891.
[PMID: 10706100]

Deryugina, E.I.; Quigley, J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev., 2006, 25(1), 9-34.
[http://dx.doi.org/10.1007/s10555-006-7886-9] [PMID: 16680569]

Zucker, S.; Hymowitz, M.; Rollo, E.E.; Mann, R.; Conner, C.E.; Cao, J.; Foda, H.D.; Tompkins, D.C.; Toole, B.P. Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am. J. Pathol., 2001, 158(6), 1921-1928.
[http://dx.doi.org/10.1016/S0002-9440(10)64660-3] [PMID: 11395366]

van ’t Veer, L.J.; Dai, H.; van de Vijver, M.J.; He, Y.D.; Hart, A.A.M.; Mao, M.; Peterse, H.L.; van der Kooy, K.; Marton, M.J.; Witteveen, A.T.; Schreiber, G.J.; Kerkhoven, R.M.; Roberts, C.; Linsley, P.S.; Bernards, R.; Friend, S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature, 2002, 415(6871), 530-536.
[http://dx.doi.org/10.1038/415530a] [PMID: 11823860]

Yousef, E.M.; Tahir, M.R.; St-Pierre, Y.; Gaboury, L.A. MMP-9 expression varies according to molecular subtypes of breast cancer. BMC Cancer, 2014, 14(1), 609.
[http://dx.doi.org/10.1186/1471-2407-14-609] [PMID: 25151367]

Venugopal, A.; Uma Maheswari, T.N. Expression of matrix metalloproteinase-9 in oral potentially malignant disorders: A systematic review. J. Oral Maxillofac. Pathol., 2016, 20(3), 474-479.
[http://dx.doi.org/10.4103/0973-029X.190951] [PMID: 27721614]

Gong, L.; Wu, D.; Zou, J.; Chen, J.; Chen, L.; Chen, Y.; Ni, C.; Yuan, H. Prognostic impact of serum and tissue MMP-9 in non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget, 2016, 7(14), 18458-18468.
[http://dx.doi.org/10.18632/oncotarget.7607] [PMID: 26918342]

Verma, S.; Kesh, K.; Gupta, A.; Swarnakar, S. An overview of matrix metalloproteinase 9 polymorphism and gastric cancer risk. Asian Pac. J. Cancer Prev., 2015, 16(17), 7393-7400.
[http://dx.doi.org/10.7314/APJCP.2015.16.17.7393] [PMID: 26625734]

Dasari, S.; Wudayagiri, R.; Valluru, L. Cervical cancer: Biomarkers for diagnosis and treatment. Clin. Chim. Acta, 2015, 445, 7-11.
[http://dx.doi.org/10.1016/j.cca.2015.03.005] [PMID: 25773118]

Yu, D.C.; Chen, J.; Ding, Y.T. Hypoxic and highly angiogenic non-tumor tissues surrounding hepatocellular carcinoma: The ‘niche’ of endothelial progenitor cells. Int. J. Mol. Sci., 2010, 11(8), 2901-2909.
[http://dx.doi.org/10.3390/ijms11082901] [PMID: 21152281]

Okamoto, T.; Sanda, T.; Asamitsu, K. NF-kappa B signaling and carcinogenesis. Curr. Pharm. Des., 2007, 13(5), 447-462.
[http://dx.doi.org/10.2174/138161207780162944] [PMID: 17348842]

Batra, J.; Robinson, J.; Mehner, C.; Hockla, A.; Miller, E.; Radisky, D.C.; Radisky, E.S. PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1). PLoS One, 2012, 7(11), e50028.
[http://dx.doi.org/10.1371/journal.pone.0050028] [PMID: 23185522]

Zhao, S.; Ma, W.; Zhang, M.; Tang, D.; Shi, Q.; Xu, S.; Zhang, X.; Liu, Y.; Song, Y.; Liu, L.; Zhang, Q. High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients. Med. Oncol., 2013, 30(1), 335.
[http://dx.doi.org/10.1007/s12032-012-0335-4] [PMID: 23263825]

Ren, F.; Tang, R.; Zhang, X.; Madushi, W.M.; Luo, D.; Dang, Y.; Li, Z.; Wei, K.; Chen, G. Overexpression of MMP family members functions as prognostic biomarker for breast cancer patients: A systematic review and meta-analysis. PLoS One, 2015, 10(8), e0135544.
[http://dx.doi.org/10.1371/journal.pone.0135544] [PMID: 26270045]

Reggiani, F.; Labanca, V.; Mancuso, P.; Rabascio, C.; Talarico, G.; Orecchioni, S.; Manconi, A.; Bertolini, F. Adipose progenitor cell secretion of GM-CSF and MMP9 promotes a stromal and immunological microenvironment that supports breast cancer progression. Cancer Res., 2017, 77(18), 5169-5182.
[http://dx.doi.org/10.1158/0008-5472.CAN-17-0914] [PMID: 28754674]

Tan, H.; Zhang, M.; Xu, L.; Zhang, X.; Zhao, Y. Gypensapogenin H suppresses tumor growth and cell migration in triple-negative breast cancer by regulating PI3K/AKT/NF-κB/MMP-9 signaling pathway. Bioorg. Chem., 2022, 126, 105913.
[http://dx.doi.org/10.1016/j.bioorg.2022.105913] [PMID: 35671647]

Gautam, J.; Banskota, S.; Lee, H.; Lee, Y.J.; Jeon, Y.H.; Kim, J.A.; Jeong, B.S. Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis. Exp. Mol. Med., 2018, 50(9), 1-14.
[http://dx.doi.org/10.1038/s12276-018-0135-9] [PMID: 30185799]

Zhou, R.; Xu, L.; Ye, M.; Liao, M.; Du, H.; Chen, H. Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways. Horm. Metab. Res., 2014, 46(11), 753-760.
[http://dx.doi.org/10.1055/s-0034-1376977] [PMID: 24977660]

Zhu, X.; Wang, K.; Zhang, K.; Xu, F.; Yin, Y.; Zhu, L.; Zhou, F. Galectin-1 knockdown in carcinoma-associated fibroblasts inhibits migration and invasion of human MDA-MB-231 breast cancer cells by modulating MMP-9 expression. Acta Biochim. Biophys. Sin., 2016, 48(5), 462-467.
[http://dx.doi.org/10.1093/abbs/gmw019] [PMID: 27025601]

Kwon, M.J. Matrix metalloproteinases as therapeutic targets in breast cancer. Front. Oncol., 2023, 12, 1108695.
[http://dx.doi.org/10.3389/fonc.2022.1108695] [PMID: 36741729]

Juric, V.; O’Sullivan, C.; Stefanutti, E.; Kovalenko, M.; Greenstein, A.; Barry-Hamilton, V.; Mikaelian, I.; Degenhardt, J.; Yue, P.; Smith, V.; Mikels-Vigdal, A. MMP-9 inhibition promotes anti-tumor immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumors. PLoS One, 2018, 13(11), e0207255.
[http://dx.doi.org/10.1371/journal.pone.0207255] [PMID: 30500835]

Ling, B.; Watt, K.; Banerjee, S.; Newsted, D.; Truesdell, P.; Adams, J.; Sidhu, S.S.; Craig, A.W.B. A novel immunotherapy targeting MMP-14 limits hypoxia, immune suppression and metastasis in triple-negative breast cancer models. Oncotarget, 2017, 8(35), 58372-58385.
[http://dx.doi.org/10.18632/oncotarget.17702] [PMID: 28938563]

Matsumoto, H.; Koo, S.; Dent, R.; Tan, P.H.; Iqbal, J. Role of inflammatory infiltrates in triple negative breast cancer: Table 1. J. Clin. Pathol., 2015, 68(7), 506-510.
[http://dx.doi.org/10.1136/jclinpath-2015-202944] [PMID: 25750267]

Carswell, E.A.; Old, L.J.; Kassel, R.L.; Green, S.; Fiore, N.; Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci., 1975, 72(9), 3666-3670.
[http://dx.doi.org/10.1073/pnas.72.9.3666] [PMID: 1103152]

Bradley, J.R. TNF‐mediated inflammatory disease. J. Pathol., 2008, 214(2), 149-160.
[http://dx.doi.org/10.1002/path.2287] [PMID: 18161752]

Van Herreweghe, F.; Festjens, N.; Declercq, W.; Vandenabeele, P. Tumor necrosis factor-mediated cell death: to break or to burst, that’s the question. Cell. Mol. Life Sci., 2010, 67(10), 1567-1579.
[http://dx.doi.org/10.1007/s00018-010-0283-0] [PMID: 20198502]

Li, H.H.; Zhu, H.; Liu, L.S.; Huang, Y.; Guo, J.; Li, J.; Sun, X.P.; Chang, C.X.; Wang, Z.H.; Zhai, K. Tumour necrosis factor-α gene polymorphism is associated with metastasis in patients with triple negative breast cancer. Sci. Rep., 2015, 5(1), 10244.
[http://dx.doi.org/10.1038/srep10244] [PMID: 26165253]

Spriggs, DR; Deutsch, S.; Kufe, D.W. Genomic structure, induction, and production of TNF-alpha. Immunol Ser, 1992, 56, 3-34.

Yu, M.; Zhou, X.; Niu, L.; Lin, G.; Huang, J.; Zhou, W.; Gan, H.; Wang, J.; Jiang, X.; Yin, B.; Li, Z. Targeting transmembrane TNF-α suppresses breast cancer growth. Cancer Res., 2013, 73(13), 4061-4074.
[http://dx.doi.org/10.1158/0008-5472.CAN-12-3946] [PMID: 23794706]

Szlosarek, P.W.; Balkwill, F.R. Tumour necrosis factor α: A potential target for the therapy of solid tumours. Lancet Oncol., 2003, 4(9), 565-573.
[http://dx.doi.org/10.1016/S1470-2045(03)01196-3] [PMID: 12965278]

Pileczki, V.; Braicu, C.; Gherman, C.; Berindan-Neagoe, I. TNF-α gene knockout in triple negative breast cancer cell line induces apoptosis. Int. J. Mol. Sci., 2012, 14(1), 411-420.
[http://dx.doi.org/10.3390/ijms14010411] [PMID: 23263670]

Martínez-Reza, I.; Díaz, L.; Barrera, D.; Segovia-Mendoza, M.; Pedraza-Sánchez, S.; Soca-Chafre, G.; Larrea, F.; García-Becerra, R. Calcitriol inhibits the proliferation of triple-negative breast cancer cells through a mechanism involving the proinflammatory cytokines IL-1 β and TNF- α. J. Immunol. Res., 2019, 2019, 1-11.
[http://dx.doi.org/10.1155/2019/6384278] [PMID: 31093512]

Zheng, M.; Wu, Z.; Wu, A.; Huang, Z.; He, N.; Xie, X. MiR-145 promotes TNF-α-induced apoptosis by facilitating the formation of RIP1-FADDcaspase-8 complex in triple-negative breast cancer. Tumour Biol., 2016, 37(7), 8599-8607.
[http://dx.doi.org/10.1007/s13277-015-4631-4] [PMID: 26733177]

Greish, K.; Taurin, S.; Morsy, M.A. The effect of adjuvant therapy with TNF-α on animal model of triple-negative breast cancer. Ther. Deliv., 2018, 9(5), 333-342.
[http://dx.doi.org/10.4155/tde-2017-0101] [PMID: 29681232]

Mendonca, P.; Alghamdi, S.; Messeha, S.; Soliman, K.F.A. Pentagalloyl glucose inhibits TNF-α-activated CXCL1/GRO-α expression and induces apoptosis-related genes in triple-negative breast cancer cells. Sci. Rep., 2021, 11(1), 5649.
[http://dx.doi.org/10.1038/s41598-021-85090-z] [PMID: 33707603]

Liu, J.; Wang, P.; Huang, B.; Cheng, Q.; Duan, Y.; Chen, L.; Ma, T.; Zhu, C.; Li, D.; Fan, W.; Yu, M. Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody. Int. J. Pharm., 2022, 624, 121969.
[http://dx.doi.org/10.1016/j.ijpharm.2022.121969] [PMID: 35803533]

Martínez-Reza, I.; Díaz, L.; García-Becerra, R. Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer. J. Biomed. Sci., 2017, 24(1), 90.
[http://dx.doi.org/10.1186/s12929-017-0398-9] [PMID: 29202842]

Wu, X.; Wu, M.Y.; Jiang, M.; Zhi, Q.; Bian, X.; Xu, M.D.; Gong, F.R.; Hou, J.; Tao, M.; Shou, L.M.; Duan, W.; Chen, K.; Shen, M.; Li, W. TNF-α sensitizes chemotherapy and radiotherapy against breast cancer cells. Cancer Cell Int., 2017, 17(1), 13.
[http://dx.doi.org/10.1186/s12935-017-0382-1] [PMID: 28127258]

Libutti, S.K.; Paciotti, G.F.; Byrnes, A.A.; Alexander, H.R., Jr; Gannon, W.E.; Walker, M.; Seidel, G.D.; Yuldasheva, N.; Tamarkin, L. Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin. Cancer Res., 2010, 16(24), 6139-6149.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-0978] [PMID: 20876255]

Tesarová, P.; Kvasnicka, J.; Umlaufová, A.; Homolková, H.; Jirsa, M.; Tesar, V.; Soluble, T.N.F. Soluble TNF and IL-2 receptors in patients with breast cancer. Med. Sci. Monit., 2000, 6(4), 661-667.
[PMID: 11208388]

Kesler, S.; Janelsins, M.; Koovakkattu, D.; Palesh, O.; Mustian, K.; Morrow, G.; Dhabhar, F.S. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav. Immun., 2013, 30, S109-S116.
[http://dx.doi.org/10.1016/j.bbi.2012.05.017] [PMID: 22698992]

Hayslip, J.; Dressler, E.V.; Weiss, H.; Taylor, T.J.; Chambers, M.; Noel, T.; Miriyala, S.; Keeney, J.T.R.; Ren, X.; Sultana, R.; Vore, M.; Butterfield, D.A.; St Clair, D.; Moscow, J.A. Plasma TNF-α and soluble TNF receptor levels after doxorubicin with or without Co-administration of mesna—a randomized, cross-over clinical study. PLoS One, 2015, 10(4), e0124988.
[http://dx.doi.org/10.1371/journal.pone.0124988] [PMID: 25909710]

Lebrec, H.; Ponce, R.; Preston, B.D.; Iles, J.; Born, T.L.; Hooper, M. Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk. Curr. Med. Res. Opin., 2015, 31(3), 557-574.
[http://dx.doi.org/10.1185/03007995.2015.1011778] [PMID: 25651481]

Sloan, E.K.; Priceman, S.J.; Cox, B.F.; Yu, S.; Pimentel, M.A.; Tangkanangnukul, V.; Arevalo, J.M.G.; Morizono, K.; Karanikolas, B.D.W.; Wu, L.; Sood, A.K.; Cole, S.W. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res., 2010, 70, 7042-7052.
[http://dx.doi.org/10.1158/0008-5472.CAN-10-0522]

Perron, L.; Bairati, I.; Harel, F.; Meyer, F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control, 2004, 15(6), 535-541.
[http://dx.doi.org/10.1023/B:CACO.0000036152.58271.5e] [PMID: 15280632]

Algazi, M.; Plu-Bureau, G.; Flahault, A.; Dondon, M.G.; Lê, M.G. Could β-blocker treatments be associated with a reduction in cancer risk? Rev. Epidemiol. Sante Publique, 2004, 52(1), 53-65.
[http://dx.doi.org/10.1016/S0398-7620(04)99022-0] [PMID: 15107693]

Powe, D.G.; Voss, M.J.; Zänker, K.S.; Habashy, H.O.; Green, A.R.; Ellis, I.O.; Entschladen, F. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget, 2010, 1(7), 628-638.
[http://dx.doi.org/10.18632/oncotarget.197] [PMID: 21317458]

Barron, T.I.; Connolly, R.M.; Sharp, L.; Bennett, K.; Visvanathan, K. Beta blockers and breast cancer mortality: A population- based study. J. Clin. Oncol., 2011, 29(19), 2635-2644.
[http://dx.doi.org/10.1200/JCO.2010.33.5422] [PMID: 21632503]

Melhem-Bertrandt, A.; Chavez-MacGregor, M.; Lei, X.; Brown, E.N.; Lee, R.T.; Meric-Bernstam, F.; Sood, A.K.; Conzen, S.D.; Hortobagyi, G.N.; Gonzalez-Angulo, A.M. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J. Clin. Oncol., 2011, 29(19), 2645-2652.
[http://dx.doi.org/10.1200/JCO.2010.33.4441] [PMID: 21632501]

Choy, C.; Raytis, J.L.; Smith, D.D.; Duenas, M.; Neman, J.; Jandial, R.; Lew, M.W. Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative β-blockade. Oncol. Rep., 2016, 35(6), 3135-3142.
[http://dx.doi.org/10.3892/or.2016.4710] [PMID: 27035124]

Powe, D.G.; Entschladen, F. Using β-blockers to inhibit breast cancer progression. Nat. Rev. Clin. Oncol., 2011, 8(9), 511-512.
[http://dx.doi.org/10.1038/nrclinonc.2011.123] [PMID: 21808268]

Ganz, P.A.; Cole, S.W. Expanding our therapeutic options: Beta blockers for breast cancer? J. Clin. Oncol., 2011, 29(19), 2612-2616.
[http://dx.doi.org/10.1200/JCO.2011.35.8820] [PMID: 21632500]

Roger, S.Ã.; Gillet, L.; Le Guennec, J.Y.; Besson, P. Voltage-gated sodium channels and cancer: Is excitability their primary role? Front. Pharmacol., 2015, 6, 152.
[http://dx.doi.org/10.3389/fphar.2015.00152] [PMID: 26283962]

Luo, Q.; Wu, T.; Wu, W.; Chen, G.; Luo, X.; Jiang, L.; Tao, H.; Rong, M.; Kang, S.; Deng, M. The functional role of voltage-gated sodium channel Nav1.5 in metastatic breast cancer. Front. Pharmacol., 2020, 11, 1111.
[http://dx.doi.org/10.3389/fphar.2020.01111] [PMID: 32792949]

Brackenbury, W.J.; Chioni, A.M.; Diss, J.K.J.; Djamgoz, M.B.A. The neonatal splice variant of Nav1.5 potentiates in vitro invasive behaviour of MDA-MB-231 human breast cancer cells. Breast Cancer Res. Treat., 2007, 101(2), 149-160.
[http://dx.doi.org/10.1007/s10549-006-9281-1] [PMID: 16838113]

Yang, M.; Kozminski, D.J.; Wold, L.A.; Modak, R.; Calhoun, J.D.; Isom, L.L.; Brackenbury, W.J. Therapeutic potential for phenytoin: Targeting Nav1.5 sodium channels to reduce migration and invasion in metastatic breast cancer. Breast Cancer Res. Treat., 2012, 134(2), 603-615.
[http://dx.doi.org/10.1007/s10549-012-2102-9] [PMID: 22678159]

Fairhurst, C.; Watt, I.; Martin, F.; Bland, M.; Brackenbury, W.J. Sodium channel-inhibiting drugs and survival of breast, colon and prostate cancer: A population-based study. Sci. Rep., 2015, 5(1), 16758.
[http://dx.doi.org/10.1038/srep16758] [PMID: 26577038]

Neligan, A.; Bell, G.S.; Johnson, A.L.; Goodridge, D.M.; Shorvon, S.D.; Sander, J.W. The long-term risk of premature mortality in people with epilepsy. Brain, 2011, 134(2), 388-395.
[http://dx.doi.org/10.1093/brain/awq378] [PMID: 21278406]

Onkal, R.; Djamgoz, M.B.A. Molecular pharmacology of voltage-gated sodium channel expression in metastatic disease: Clinical potential of neonatal Nav1.5 in breast cancer. Eur. J. Pharmacol., 2009, 625(1-3), 206-219.
[http://dx.doi.org/10.1016/j.ejphar.2009.08.040] [PMID: 19835862]

Djamgoz, M.B.A.; Onkal, R. Persistent current blockers of voltage-gated sodium channels: A clinical opportunity for controlling metastatic disease. PRA, 2013, 8(1), 66-84.
[http://dx.doi.org/10.2174/1574892811308010066] [PMID: 23116083]

Zha, C.; Brown, G.B.; Brouillette, W.J. A highly predictive 3D-QSAR model for binding to the voltage-gated sodium channel: Design of potent new ligands. Bioorg. Med. Chem., 2014, 22(1), 95-104.
[http://dx.doi.org/10.1016/j.bmc.2013.11.049] [PMID: 24332655]

Dutta, S.; Lopez Charcas, O.; Tanner, S.; Gradek, F.; Driffort, V.; Roger, S.; Selander, K.; Velu, S.E.; Brouillette, W. Discovery and evaluation of nNa_v1.5 sodium channel blockers with potent cell invasion inhibitory activity in breast cancer cells. Bioorg. Med. Chem., 2018, 26(9), 2428-2436.
[http://dx.doi.org/10.1016/j.bmc.2018.04.003] [PMID: 29673714]

Cazales, M.; Schmitt, E.; Montembault, E.; Dozier, C.; Prigent, C.; Ducommun, B. CDC25B phosphorylation by Aurora-A occurs at the G2/M transition and is inhibited by DNA damage. Cell Cycle, 2005, 4(9), 1233-1238.
[http://dx.doi.org/10.4161/cc.4.9.1964] [PMID: 16082213]

Krystyniak, A.; Garcia-Echeverria, C.; Prigent, C.; Ferrari, S. Inhibition of Aurora A in response to DNA damage. Oncogene, 2006, 25(3), 338-348.
[http://dx.doi.org/10.1038/sj.onc.1209056] [PMID: 16158051]

Cimprich, K.A.; Cortez, D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol., 2008, 9(8), 616-627.
[http://dx.doi.org/10.1038/nrm2450] [PMID: 18594563]

Foote, K.M.; Lau, A.; M Nissink, J.W.; Drugging, A.T.R. Drugging ATR: Progress in the development of specific inhibitors for the treatment of cancer. Future Med. Chem., 2015, 7(7), 873-891.
[http://dx.doi.org/10.4155/fmc.15.33] [PMID: 26061106]

Barnieh, F.M.; Loadman, P.M.; Falconer, R.A. Progress towards a clinically-successful ATR inhibitor for cancer therapy. CRPHAR, 2021, 2, 100017.
[http://dx.doi.org/10.1016/j.crphar.2021.100017] [PMID: 34909652]

Wilson, Z.; Odedra, R.; Wallez, Y.; Wijnhoven, P.W.G.; Hughes, A.M.; Gerrard, J.; Jones, G.N.; Bargh-Dawson, H.; Brown, E.; Young, L.A.; O’Connor, M.J.; Lau, A.; Inhibitor, A.T.R. ATR inhibitor AZD6738 (Ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib. Cancer Res., 2022, 82(6), 1140-1152.
[http://dx.doi.org/10.1158/0008-5472.CAN-21-2997] [PMID: 35078817]

Tu, X.; Kahila, M.M.; Zhou, Q.; Yu, J.; Kalari, K.R.; Wang, L.; Harmsen, W.S.; Yuan, J.; Boughey, J.C.; Goetz, M.P.; Sarkaria, J.N.; Lou, Z.; Mutter, R.W. ATR inhibition is a promising radiosensitizing strategy for triple negative breast cancer. Mol. Cancer Ther., 2018, 17(11), 2462-2472.
[http://dx.doi.org/10.1158/1535-7163.MCT-18-0470] [PMID: 30166399]

Al-Subhi, N.; Ali, R.; Abdel-Fatah, T.; Moseley, P.M.; Chan, S.Y.T.; Green, A.R.; Ellis, I.O.; Rakha, E.A.; Madhusudan, S. Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy. Breast Cancer Res. Treat., 2018, 169(2), 277-286.
[http://dx.doi.org/10.1007/s10549-018-4683-4] [PMID: 29396668]

de Nonneville, A.; Finetti, P.; Birnbaum, D.; Mamessier, E.; Bertucci, F. WEE1 dependency and pejorative prognostic value in triple‐negative breast cancer. Adv. Sci., 2021, 8(17), 2101030.
[http://dx.doi.org/10.1002/advs.202101030] [PMID: 34227743]

Jin, J.; Fang, H.; Yang, F.; Ji, W.; Guan, N.; Sun, Z.; Shi, Y.; Zhou, G.; Guan, X. Combined inhibition of ATR and WEE1 as a novel therapeutic strategy in triple-negative breast cancer. Neoplasia, 2018, 20(5), 478-488.
[http://dx.doi.org/10.1016/j.neo.2018.03.003] [PMID: 29605721]

Chen, X.; Low, K.H.; Alexander, A.; Jiang, Y.; Karakas, C.; Hess, K.R.; Carey, J.P.W.; Bui, T.N.; Vijayaraghavan, S.; Evans, K.W.; Yi, M.; Ellis, D.C.; Cheung, K.L.; Ellis, I.O.; Fu, S.; Meric-Bernstam, F.; Hunt, K.K.; Keyomarsi, K.; Cyclin, E. Cyclin E overexpression sensitizes triple-negative breast cancer to wee1 kinase inhibition. Clin. Cancer Res., 2018, 24(24), 6594-6610.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-1446] [PMID: 30181387]

Yang, G.J.; Zhong, H.J.; Ko, C.N.; Wong, S.Y.; Vellaisamy, K.; Ye, M.; Ma, D.L.; Leung, C.H. Identification of a rhodium( III ) complex as a Wee1 inhibitor against TP53 -mutated triple-negative breast cancer cells. Chem. Commun., 2018, 54(20), 2463-2466.
[http://dx.doi.org/10.1039/C7CC09384E] [PMID: 29367998]

Hwang, S.Y.; Park, S.; Kwon, Y. Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacol. Ther., 2019, 199, 30-57.
[http://dx.doi.org/10.1016/j.pharmthera.2019.02.006] [PMID: 30825473]

Chen, P.; Luo, C.; Deng, Y.; Ryan, K.; Register, J.; Margosiak, S.; Tempczyk-Russell, A.; Nguyen, B.; Myers, P.; Lundgren, K.; Kan, C.C.; O’Connor, P.M. The 1.7 A crystal structure of human cell cycle checkpoint kinase Chk1: implications for Chk1 regulation. Cell, 2000, 100(6), 681-692.
[http://dx.doi.org/10.1016/S0092-8674(00)80704-7] [PMID: 10761933]

Liu, Q.; Guntuku, S.; Cui, X.S.; Matsuoka, S.; Cortez, D.; Tamai, K.; Luo, G.; Carattini-Rivera, S.; DeMayo, F.; Bradley, A.; Donehower, L.A.; Elledge, S.J. Chk1 is an essential kinase that is regulated by Atr and required for the G ₂ /M DNA damage checkpoint. Genes Dev., 2000, 14(12), 1448-1459.
[http://dx.doi.org/10.1101/gad.14.12.1448] [PMID: 10859164]

Bryant, C.; Rawlinson, R.; Massey, A.J. Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer, 2014, 14(1), 570.
[http://dx.doi.org/10.1186/1471-2407-14-570] [PMID: 25104095]

Albiges, L.; Goubar, A.; Scott, V.; Vicier, C.; Lefèbvre, C.; Alsafadi, S.; Commo, F.; Saghatchian, M.; Lazar, V.; Dessen, P.; Delaloge, S.; André, F.; Quidville, V. Chk1 as a new therapeutic target in triple-negative breast cancer. Breast, 2014, 23(3), 250-258.
[http://dx.doi.org/10.1016/j.breast.2014.02.004] [PMID: 24636978]

Rundle, S.; Bradbury, A.; Drew, Y.; Curtin, N. Targeting the ATR-CHK1 axis in cancer therapy. Cancers, 2017, 9(12), 41.
[http://dx.doi.org/10.3390/cancers9050041] [PMID: 28448462]

Bennett, C.N.; Tomlinson, C.C.; Michalowski, A.M.; Chu, I.M.; Luger, D.; Mittereder, L.R.; Aprelikova, O.; Shou, J.; Piwinica-Worms, H.; Caplen, N.J.; Hollingshead, M.G.; Green, J.E. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer. Breast Cancer Res., 2012, 14(4), R109.
[http://dx.doi.org/10.1186/bcr3230] [PMID: 22812567]

Infante, J.R.; Hollebecque, A.; Postel-Vinay, S.; Bauer, T.M.; Blackwood, E.M.; Evangelista, M.; Mahrus, S.; Peale, F.V.; Lu, X.; Sahasranaman, S.; Zhu, R.; Chen, Y.; Ding, X.; Murray, E.R.; Schutzman, J.L.; Lauchle, J.O.; Soria, J.C.; LoRusso, P.M.; Phase, I. Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors. Clin. Cancer Res., 2017, 23(10), 2423-2432.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-1782] [PMID: 27815358]

Tentler, J.J.; Ionkina, A.A.; Tan, A.C.; Newton, T.P.; Pitts, T.M.; Glogowska, M.J.; Kabos, P.; Sartorius, C.A.; Sullivan, K.D.; Espinosa, J.M.; Eckhardt, S.G.; Diamond, J.R. p53 family members regulate phenotypic response to aurora kinase A inhibition in triple-negative breast cancer. Mol. Cancer Ther., 2015, 14(5), 1117-1129.
[http://dx.doi.org/10.1158/1535-7163.MCT-14-0538-T] [PMID: 25758253]

Kai, K.; Kondo, K.; Wang, X.; Xie, X.; Pitner, M.K.; Reyes, M.E.; Torres-Adorno, A.M.; Masuda, H.; Hortobagyi, G.N.; Bartholomeusz, C.; Saya, H.; Tripathy, D.; Sen, S.; Ueno, N.T. Antitumor activity of KW-2450 against triple-negative breast cancer by inhibiting aurora A and B kinases. Mol. Cancer Ther., 2015, 14(12), 2687-2699.
[http://dx.doi.org/10.1158/1535-7163.MCT-15-0096] [PMID: 26443806]

Romanelli, A.; Clark, A.; Assayag, F.; Chateau-Joubert, S.; Poupon, M.F.; Servely, J.L.; Fontaine, J.J.; Liu, X.; Spooner, E.; Goodstal, S.; de Cremoux, P.; Bièche, I.; Decaudin, D.; Marangoni, E. Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts. Mol. Cancer Ther., 2012, 11(12), 2693-2703.
[http://dx.doi.org/10.1158/1535-7163.MCT-12-0441-T] [PMID: 23012245]

Bush, T.L.; Payton, M.; Heller, S.; Chung, G.; Hanestad, K.; Rottman, J.B.; Loberg, R.; Friberg, G.; Kendall, R.L.; Saffran, D.; Radinsky, R. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models. Mol. Cancer Ther., 2013, 12(11), 2356-2366.
[http://dx.doi.org/10.1158/1535-7163.MCT-12-1178] [PMID: 23990115]